B2BROKER
19.1.2021 11:02:47 CET | Business Wire | Press release
B2Broker , a liquidity and technology provider of solutions for the crypto and Forex industry, has added a new range of features to its matching engine, B2Trader, enabling client demands to be met in record time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005197/en/
About B2Trader
B2Trader is used by many of the world's best-known exchanges, MTF Brokers, Security Exchanges, Market Makers, Spot FX Brokers and EMIs, with the job of matching an incoming market order of the user with the existing limit order of another user. The engine works 24/7 in parallel with the round-the-clock rhythm of the crypto markets without any breaks.
Matching - Tech Stack, Details, Scheme of the Module and Capacity
The order matcher is designed for crypto trading and low-latency automatic trading systems and is able to fulfill 10,000 requests per second with an average latency of 500 ms. The new matching engine uses C # ASP.NET Core programming languages for the back-end and includes a trading mechanism for matching orders, various APIs and synchronization services and databases.
API - All Details, Languages and Capacity
The stability and performance aspects of the engine now allow for the development of faster APIs. B2Broker has introduced a new API for robotic trading and public data access which handles trading and public requests much faster while positively affecting the overall system performance (trading and public API - Websocket/Rest). With new API access, users can connect directly into the matching system and operate ultra-fast trading orders or receive crypto markets data on DOMs.
Security
B2Trader incorporates a series of the latest features to provide the best possible protection from technical and fraud threats. These include an anti-throttling system, anti-spoofing protection and DDoS protection. Other security features include 2FA, adding an extra layer of security, and an IP Whitelist which puts in place a restriction to work only under a certain IP inside the admin panel.
Front End
A professional GUI meets all requirements from beginners to pro-traders. It provides a multitude of features and a high degree of customisation including adaptive colouring, easy and highly responsive navigation menu, grouping for sorting options into a more convenient structure and a customisable Dynamic User Interface with colour and font customisation which includes easy addition of widgets, workspaces for various trading styles, widgets customization and workspace arrangement.
Some recent developments include a watchlist that allows for the addition of favourite instruments to monitor percentage changes, White/Night mode, a broad variety of deposit/withdrawal methods featuring B2BinPay , IOC/FOK order settings and the availability of multiple sources of liquidity available for connection with B2Trader.
Back Office
B2Trader admin takes care of all operational options that need to be carried out by the exchange daily, delivering them in a user-friendly and sophisticated manner. The admin module allows you to manage and set up and change exchange user trading/withdrawal permissions, extract information on the history of user logins to the exchange UI, transfer history, user asset balances, information on a user's aggregate balance in indicative currency, setup commissions for the markets or particular user and more, with safety always a top priority.
SAAS AWS
B2Trader uses hosting solutions that dynamically scale resources and support the most demanding and highly loaded projects. AWS hosting offers high levels of availability, scalability and performance, requiring higher amounts of management and administration that is fully organised by B2Broker.
Third-Party Integrations
To set up and run a successful exchange business, there needs to be an equal focus on sales and marketing, compliance, deposits, withdrawals, licenses, and the regulatory framework, etc. To this end, B2Broker has integrated a variety of services that help exchanges manage all aspects effectively. These include B2BinPay, B2Core , Crystal Blockchain, Leading Fiat PSPs, SumSub, B2BX and MarksMan.
The latest features combined with external integrations further enhance B2Trader to deliver a matching engine with the ultimate in performance and functionality, while ensuring that all market participants are given the best execution.
New clients can now benefit from a discount on setup, offering more favourable pricing than 2020 due to COVID and the new market bull run.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005197/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom